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A few novel previously synthesized 2,5-disubstituted 1,3,4-oxadiazoles with cytotoxic activity (1e17)
were subjected to combined docking/quantum mechanical studies against chemotherapeutic targets.
Selected macromolecular targets were those that were previously known to be inhibited by 1,3,4-
oxadiazoles. Within this work, favorable binding modes/afﬁnities of the oxadiazoles toward validated
cancer targets were elucidated. Some oxadiazole structures exhibited DGbs comparable to or stronger
than crystallographic ligands that were previously demonstrated to inhibit such targets. On the basis of
obtained results, a general structure activity/binding relationship (SAR/SBR) was developed and a few
2,5-disubstituted 1,3,4-oxadiazole structures were proposed and virtually validated as potential cytotoxic
candidates. To get more insight into structure binding relationship of candidate molecules within best
correlated targets, docked conformation of the best in silico in vitro correlated oxadiazole structure was
analyzed in terms of intermolecular binding energy components by functional B3LYP in association with
split valence basis set using polarization functions (Def2-SVP). We believe that such modeling studies
may be complementary to our previous results on the synthesis and cytotoxicity assessment of novel
1,3,4-oxadiazole derivatives through extending the scope of privileged structures toward designing new
potential anti-tumor compounds.
© 2018 Elsevier B.V. All rights reserved.1. Introduction
Compounds possessing diverse heterocyclic nucleuses have
obtained special signiﬁcance in drug discovery and design. Among
such privileged scaffolds, ﬁve-membered 1,3,4-oxadiazole ring has
attracted considerable concern in medicinal chemistry due to the
broad range of pharmaceutical and biological activities, such as
anticancer [1], antifungal [2], antibacterial [3], antiviral [4],
analgesic [5], anti-inﬂammatory [6], antihypertensive [7], anti-
convulsant [8] and anti-diabetic [9] effects. Moreover, various
synthetic approaches toward 1,3,4-oxadiazoles have facilitated the
investigation of their chemical and biological properties.
A number of 2,5-disubstituted 1,3,4-oxadiazole structures have
been reported to exhibit cytotoxic activity through the inhibition of
different growth factors, enzymes and kinases includingChemistry, School of Phar-
, 5618953141, Iran.
.ir, razzaghinima@gmail.comtelomerase, histone deacetylase (HDAC), methionine aminopepti-
dase (MetAP), thymidylate synthase (TS), glycogen synthase
kinase-3 (GSK), epidermal growth factor (EGF), vascular endothelial
growth factor (VEGF) and focal adhesion kinase (FAK) [10].
Among mentioned targets, the major mechanism responsible
for anticancer potency of 1,3,4-oxadiazole derivatives relates to the
inhibition of telomerase enzyme. In a few separated studies,
different 1,3,4-oxadiazole derivatives were synthesized and
screened for their telomerase inhibitory activity against MCF-7 and
other cancer cell lines. The major assessed compounds were 1,4-
benzodioxane, 2-chloro pyridine, acyl hydrazone and quinoline
containing 1,3,4-oxadiazole derivatives [11e14].
Structure activity relationship (SAR) studies of two different
series of synthetic 1,3,4-oxadiazoles revealed that for HDAC inhi-
bition three pharmacophoric requirements are zinc binding group,
linker and surface recognition cap group [15]. HDAC inhibitors can
suppress the phosphorylation of human telomerase reverse tran-
scriptase (hTRT) by protein kinase B (PKB/Akt) through regulation
of telomerase activity [16]. This can represent an innovative strat-
egy to design compounds which co-targets (PKB-Akt) and
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Study of 1,4-benzodioxane containing 1,3,4-oxadiazoles
revealed their potentiality for inhibition of telomerase, GSK-3
beta and MetAP pathway [17,18]. Likewise, benztriazol and phe-
nylethanone containing derivatives demonstrated potential FAK
inhibitory activity [19,20]. In another study, the inhibitory activity
against TS varied with the substituents on different positions of
benzene ring joined to 1,3,4-oxadiazole and increased with the
incorporation of electron withdrawing groups into the phenyl ring
[21].
It seems that pyrrole triazine analogs of 1,3,4-oxadiazole are
potential VEGF-2 inhibitors [22,23]. A series of 2,4-bis diphenyl-
amine oxadiazole derivatives have been reported with promising
EGFR tyrosine kinase inhibitory activity [24]. Moreover; it was
known that inhibition of EGFR signaling not only had an anti-
proliferative and therapeutic effects but also increased sensitivity
to cytotoxic therapies.
In continuation to our interest in structure based design of small
molecule heterocyclic structures as potential bioactive compounds,
a series of novel cytotoxic1-(5-aryl-1,3,4-oxadiazol-2-yl)-1-(1H-
pyrrol-2-yl) methanamines [25] were subjected to combined mo-
lecular docking/quantum mechanical (QM) simulations in order to
estimate their binding mode/afﬁnity toward several validated
chemotherapeutic targets. For more clariﬁcation, general proced-
ure of the work is represented schematically (Scheme 1).2. Materials and methods
2.1. Ligand data set
A series of cytotoxic 1,3,4-oxadizole derivatives (Table 1) were
subjected to in silico studies [25]. Candidate molecules were
checked in terms of Lipinski's rule of ﬁve (RO5) [26] and it was
revealed that for almost all of the compounds, no deviation from
the expected criteria occurred except for compounds 16 and 17
which exhibited a little deviation just in one of their parameters
(ClogP 5.24 & 5.51, respectively). Accordingly, the whole candidate
ligands could be classiﬁed as drug-like structures [26] (Fig. 1).Scheme 1. Schematic ﬂowchart of in silico analysis of 1,3,4-oxadiazole derivatives
within chemotherapeutic targets.2.2. Target data set
All radiographic 3D holo structures of selected targets (BCL-2,
PBD ID: 4AQ3 [27]; EGF, PDB ID: 3W33 [28]; Enoyl-acp Reductase,
PDB ID: 1QSG [29]; FAK, PDB ID: 4KAO [30]; GSK-3 beta, PDB ID:
1Q41 [31]; HDAC, PDB ID: 5IX0 [32]; MetAP, PDB ID: 1YW7 [33];
telomerase, PDB ID: 5CQG [34]; TS, PDB ID: 4E5O [35] and VEGF,
PDB ID: 3VO3 [36]) were retrieved from the Brookhaven protein
data bank (http://www.rcsb.org/) with resolutions in the range of
1.52e2.40 Å. Macromolecular structures were subjected to opti-
mization step in order to minimize the crystallographic induced
bond clashes using steepest descent method. All the pre-processing
steps were done by Auto-Dock Tools 1.5.4 (ADT) [37] according to
the previous reports [38]. The biological importance of the selected
targets with regard to cancer therapy is summarized through
separate paragraphs.
2.2.1. Bcl-2
The Bcl-2 family proteins are essential regulators of apoptosis
which dictate cellular survival or death decisions by regulating the
integrity of the mitochondrial outer membrane (MOM) [39], and
include three subgroups of proteins that either promote cell sur-
vival (e.g., Bcl-2 and Bcl-xL), initiate cell killing (e.g., Bcl-2-
interacting mediator of cell death (Bim), p53 upregulated medi-
ator of apoptosis (Puma) or Bcl-2-interacting domain (Bid) or
activate the effector pathways of apoptosis (Bax, Bak) [40]. As a
result, Bcl-2 is an anti-apoptotic protein possessing an important
role in various types of cancers like breast which is encoded by the
Bcl-2 gene [41].
2.2.2. Epidermal growth factor
Epidermal growth factor (EGF) plays a considerable role in tu-
mor development and progression, including cell proliferation,
regulation of apoptotic cell death, angiogenesis and metastatic
spread by binding to its receptor, EGFR [42]. Due to the over-
expression of EGFR in various types of epithelial cancers, like
pancreatic, colorectal, breast, and lung cancer, it has been thought
that EGFR is an appropriate target for cancer therapy [43].
2.2.3. Enoyl-acyl carrier protein reductase
Human fatty acid synthase (FAS) is a large, multi-domain protein
that synthesizes long chain fatty acids. Human enoyl-acyl carrier
protein-reductase (hENR) is one of the FAS catalytic domains, also is
the last enzyme in the fatty acid elongation cycle which reduces the
substrate enoyl-thioester to an acyl moiety [44]. Because fatty acids
are primarily provided by diet, FAS is normally expressed at low
levels. However, high levels of FAS expression have been found in
many human cancers including breast, prostate, colon, ovary and
lung [45].
2.2.4. Focal adhesion kinase
Focal adhesion kinase (FAK) is a cytoplasmic non-receptor
tyrosine kinase that is expressed ubiquitously and speciﬁcally
localized in focal adhesions [46]. Integrin-mediated FAK activation
pathway is proven to be involved in survival mechanisms and plays
a critical role in the adhesion, invasion, and metastasis of tumor
cells [47]. High expressions of FAK have been observed in both
endometrial hyperplasia and carcinoma, implying that FAK may
play an important role in epithelial-mesenchymal transition (EMT)
and migration during endometrial carcinogenesis [48].
2.2.5. Glycogen synthase kinase 3 beta
Glycogen synthase kinase-3 (GSK-3) is a moon-lighting kinase
which phosphorylates multiple proteins on serine and threonine
residues [49]. The GSK-3 gene family consists of two highly
Table 1
Chemical structures of 1-(5-aryl-1,3,4-oxadiazol-2-yl)-1-(1H-pyrrol-2-yl) methanamines.
Comp. Code R1 R2 MW logP No. HBDa No. HBAb No. RTBs
1 H H 330.38 3.56 2 5 6
2 H m-Cl 364.83 4.12 2 5 6
3 H p-Cl 364.83 4.12 2 5 6
4 H 3,4-Cl2 399.27 4.68 2 5 6
5 H 2,4-Cl2 5-F 417.26 4.84 2 5 6
6 H p-Br 409.28 4.39 2 5 6
7 H p-CH3 344.41 4.05 2 5 6
8 H m-CH3 344.41 4.05 2 5 6
9 H p-OCH3 360.41 3.44 2 6 7
10 H 2,4-(OCH3)2 390.44 3.31 2 7 8
11 o-OCH3 H 360.41 3.44 2 6 7
12 p-OCH3 H 360.41 3.44 2 6 7
13 p-OCH3 m-Cl 394.85 3.99 2 6 7
14 p-CH3 p-Br 423.31 4.88 2 5 6
15 p-F p-OCH3 378.4 3.59 2 6 7
16 3,4-Cl2 m-Cl 433.72 5.24 2 5 6
17 3,4-Cl2 p-Br 478.17 5.51 2 5 6
a H-bond donor
b H-bond acceptor
Fig. 1. Distribution patterns of 1-(5-aryl-1,3,4-oxadiazol-2-yl)-1-(1H-pyrrol-2-yl)
methanamines with regard to RO5 (red circle: MW vs ClogP, blue circle: MW vs HBA,
blue triangle: MW vs HBD).
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roles. Suppression of GSK-3 beta expression inhibited pancreatic
cancer growth and angiogenesis. GSK-3 inhibitors may be appro-
priate for treatment of tumors exhibiting GSK-3 overexpression in
which GSK-3 is acting as a tumor promoter [50].2.2.6. Histone deacetylase
A common ﬁnding in cancer cells is high level expression of
HDAC isoenzymes and a corresponding hypoacetylation of histones
[51]. HDAC2 expression is elevated in colon cancer cells, possibly as
a result of adenomatosis polyposis coli (APC) gene deﬁciency, an
early event in colon carcinogenesis [52]. Mutation and/or aberrant
expression of various HDACs have often been observed in human
disease, in particular cancer, making them important therapeutic
targets for many human cancers [53].2.2.7. Methionine amino peptidase
The methionine aminopeptidases (MetAPs) represent a unique
class of proteases. Key active site residues and a dinuclear metal
center facilitate the removal of the N-terminal initiator methionine
from nascent polypeptides [54]. MetAps initiate co- and post-
translational modiﬁcations that are essential for the translation,
activation, regulation and degradation of proteins in eukaryotic
cells [55]. In eukaryotes, there are two genes encoding MetAP,
MetAP1 and MetAP2. MetAP2 has attracted much more attention
thanMetAP1 due to the discovery of MetAP2 as a target molecule of
the anti-angiogenic compounds, fumagillin and ovalicin [56]. High
expression of MetAP2 has been demonstrated in breast and colo-
rectal cancer [57,58].
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Telomerase is a ribonucleoprotein that acts to elongate
telomeres in cells that possess its activity. This enzyme is expressed
during embryonic development, loses its expression during
differentiation of somatic cells, and is almost undetectable in most
normal human somatic cells [59]. Telomerase is expressed in more
than 85% of human cancer cells and the level of its activity is higher
in advanced and metastatic tumors [60]. Thus, it allows cells to
escape from the inhibition of cell proliferation due to shortened
telomeres. The widespread expression of telomerase in a variety of
human cancers, while being almost undetectable in most normal
cells, makes it a very attractive drug target [61].
2.2.9. Thymidylate synthase
TS, a homodimer with one active site in each monomer, plays a
central role in the biosynthesis of thymidylate, an essential
precursor for DNA synthesis and repair. Inhibition of TS disrupts
DNA replication, leading to thymine less death in proliferating cells
[62]. Ligand-free TS protein binds its own mRNA and thereby
represses translation [63]. TS protein and mRNA levels are elevated
in many human cancers, and high TS levels have been illustrated in
colorectal, breast, cervical, bladder, kidney, and non-small cell lung
cancers.
2.2.10. Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) and its cognate
receptor (VEGFR-2) are the most prominent regulators of angio-
genesis [64], and are highly expressed in most solid tumors,
including prostate cancer. VEGF signaling stimulates cellular
pathways that lead to the formation and branching of new tumor
blood vessels, promotes rapid tumor growth, and facilitates meta-
static potential [65]. Due to the multifaceted effect VEGF has on
tumor angiogenesis, tumor cell proliferation, and bone destruction,
it has become a rational target for anticancer therapy [66].
2.3. Molecular docking study
Lamarckian genetic algorithm (LGA) of AutoDock 4.2 [67,68] was
used to simulate the binding afﬁnity and binding mode of 1,3,4-
oxadiazole derivatives in the active site of decuple targets. On the
basis of internal validation study, ﬁfty independent genetic algo-
rithm (GA) runs were considered for each ligand under study,
except in the case of Bcl-2 for which 100 GA runs were considered.
For LGA; 27000 maximum generations; a gene mutation rate of
0.02; and a crossover rate of 0.8 were applied. AutoGrid was used to
estimate the grid maps of the protein. For this purpose, on the basis
of the volumes of candidate molecules, a grid of 40 40 40 points
in x, y, and z directions was built centered on the center of mass of
the catalytic site of intended co-crystallographic ligands (spacing:
0.375 Å). Cluster analysis was performed on the docked resultsTable 2
AutoDock 4.2 validation results for different holo PDB structures of intended chemother
No. Target PDB ID Resolution of PDB
structure (Å)
Estimated Ki(mM)
1 Bcl-2 4AQ3 2.40 7.68 104
2 EGF 3W33 1.70 3.58 104
3 ENR 1QSG 1.75 0.348
4 FAK 4KAO 2.39 3.61 104
5 GSK-3 beta 1Q41 2.10 0.0851
6 HDAC 5IX0 1.72 0.008
7 MetAP 1YW7 1.85 15.40
8 Telomerase 5CQG 2.30 0.015
9 TS 4E5O 1.70 4.07
10 VEGF 3VO3 1.52 2.50 104using a root mean square deviation (RMSD) threshold of 2 Å. The
best docking result in each case was considered to be the confor-
mation with the lowest binding energy. Schematic 2D representa-
tions of the ligand-receptor interactions were recorded by LIGPLOT
[69].
2.4. QM simulation
Simulated amino acid residues were considered on the basis of
detected interacted components of docked top-ranked oxadiazole
compounds. To mimic the real electronic state of all involved res-
idues, N-terminals and C-terminals were acetylated and methyl
amidated respectively to imitate the original electron density. Due
to the unclear position of H-bonds in a typical X-ray crystallo-
graphic ﬁle, we further optimized the heavy atom/H-bonds by the
same method and basis set using heavy atom ﬁxing approximation
method (constrained optimizations) [70]. All the interaction en-
ergies were estimated through functional B3LYP associated with
split valence basis set using polarization functions (Def2-SVP)
incorporated into ORCA quantum chemistry package [71].
3. Results and discussion
3.1. Molecular docking
Available X-ray crystallographic data on Protein Data Bank (PDB)
simpliﬁed the structure based design of desired enzyme inhibitors
by docking simulation which is a key tool in structural molecular
biology and computer-assisted drug design (CADD) [72]. Numerous
successful applications of molecular docking in drug discovery ef-
forts have been reported [73]. AutoDock is well established docking
software which has offered several fruitful advantages in designing
bioactive compounds (http://autodock.scripps.edu) [74].
3.1.1. Internal validation
The validity of the method was interpreted in terms of RMSD of
the ligand atoms in the re-docked and crystallographic conforma-
tions [75] (Table 2). For comparison purposes, crystallographic and
docked poses of ligands are depicted in Fig. 2.
3.1.2. Estimated binding afﬁnities & in silico in vitro correlation
To calculate the binding afﬁnities of 1,3,4-oxadiazoles (1e17)
toward selected targets, all the ligand structures were docked into
the active site of desired receptors. In all simulations, it was assured
that top-ranked docking outputs were supported by high cluster
populations. Results are summarized in Table 3. Besides free
binding energy, to consider compounds that use their atoms more
efﬁciently in binding to target, ligand efﬁciency (LE) indices which
are indicative of binding afﬁnity with regard to number of heavy
atoms [76] were also estimated via Eq. (1) in which HAC stands forapeutic targets.
RMSD from
Reference (Å)
No. GA runs No. conformations in
top-ranked cluster
Max. No. energy
eval.
1.68 100 23 3 106
0.74 50 30 2.5 106
0.36 50 50 2.5 106
0.49 50 50 2.5 106
0.47 50 50 2.5 106
0.86 50 50 2.5 106
0.74 50 40 2.5 106
0.94 50 19 2.5 106
0.56 50 19 2.5 106
0.49 50 21 2.5 106
Fig. 2. Binding poses of cognate ligands within active site of relevant targets in docked ( ) and crystallographic ( ) states; a) Bcl-2, RMSD 1.68 Å, b) EGF, RMSD 0.74 Å, c) ENR,
RMSD 0.36 Å, d) FAK, RMSD 0.49 Å, e) GSK-3 beta, RMSD 0.47 Å, f) HDAC, RMSD 0.86 Å, g) MetAP, RMSD 0.74 Å, h) Telomerase, RMSD 0.94 Å, i) TS, RMSD 0.56 Å, j) VEGF, RMSD
0.49 Å.
Table 3
Docking simulation results of oxadiazoles against chemotherapeutic targets (HAC: heavy atom count; LE: ligand efﬁciency)
Ligand code HAC BCL-2 EGF ENR FAK GSK-3 beta
Ki (mM) DGb (kcal/mol) LE Ki (mM) DGb (kcal/mol) LE Ki (mM) DGb (kcal/mol) LE Ki (mM) DGb (kcal/mol) LE Ki (mM) DGb (kcal/mol) LE
1 25 16.50 6.52 0.26 0.152 9.30 0.37 0.094 5.50 0.22 0.079 9.69 0.39 0.394 8.74 0.35
2 26 14.17 6.61 0.25 0.057 9.88 0.38 0.001 8.08 0.31 0.153 9.30 0.36 0.221 9.08 0.35
3 26 11.75 6.73 0.26 0.051 9.94 0.38 0.685 8.41 0.32 0.156 9.29 0.36 0.171 8.32 0.32
4 27 3.66 7.42 0.27 0.017 10.59 0.39 0.115 9.46 0.35 0.056 9.90 0.37 0.497 9.96 0.37
5 28 7.78 6.97 0.25 0.028 10.31 0.37 0.238 9.04 0.32 0.114 9.47 0.34 1.04 8.16 0.29
6 26 10.81 6.78 0.26 0.035 10.18 0.39 0.241 9.03 0.35 0.104 9.52 0.37 0.064 9.81 0.38
7 26 18.97 6.44 0.25 0.066 9.79 0.38 0.447 8.66 0.33 0.196 9.15 0.35 0.144 9.33 0.36
8 26 7.45 7.00 0.27 0.072 9.75 0.36 0.554 8.54 0.33 0.047 10.00 0.38 0.296 8.91 0.34
9 27 18.78 6.45 0.24 0.066 9.80 0.36 0.318 8.86 0.33 0.282 8.94 0.33 0.141 9.35 0.35
10 29 13.25 6.65 0.23 0.052 9.93 0.34 0.991 8.19 0.28 0.185 9.19 0.32 0.213 9.10 0.31
11 27 15.86 6.55 0.24 0.061 9.84 0.36 0.461 8.64 0.32 0.106 9.51 0.35 0.950 8.22 0.30
12 27 10.32 6.80 0.25 0.174 9.22 0.34 0.397 8.73 0.32 0.028 10.30 0.38 1.45 8.44 0.31
13 28 10.19 6.81 0.24 0.111 9.49 0.34 0.609 8.48 0.30 0.129 9.40 0.34 0.581 8.51 0.30
14 27 7.53 6.99 0.26 0.017 10.60 0.39 0.484 8.61 0.32 0.124 9.44 0.35 0.470 9.66 0.36
15 28 24.70 6.29 0.24 0.078 9.70 0.35 0.001 8.17 0.29 0.311 8.88 0.32 1.21 8.07 0.29
16 28 3.07 7.52 0.27 0.013 10.74 0.38 0.322 8.86 0.32 0.058 9.87 0.35 0.136 9.37 0.33
17 28 1.52 7.92 0.28 0.008 11.06 0.4 0.227 9.06 0.32 0.062 9.84 0.35 0.153 10.30 0.37
Ligand code HAC HDAC MetAP Telomerase TS VEGF
Ki (mM) DGb (kcal/mol) LE Ki (mM) DGb (kcal/mol) LE Ki (mM) DGb (kcal/mol) LE Ki (mM) DGb (kcal/mol) LE Ki (mM) DGb (kcal/mol) LE
1 25 2.88 7.56 0.36 0.003 11.71 0.47 6.00 7.12 0.28 0.604 8.48 0.34 0.026 10.33 0.41
2 26 0.99 8.19 0.37 7.98 104 12.41 0.48 5.39 7.19 0.28 0.581 8.51 0.33 0.042 10.07 0.39
3 26 1.03 8.17 0.37 5.34 104 12.65 0.49 3.39 7.46 0.29 1.15 8.10 0.31 0.010 10.91 0.42
4 27 0.48 8.62 0.39 5.30 104 12.65 0.47 2.13 7.74 0.29 1.17 8.09 0.30 0.004 11.39 0.42
5 28 0.698 8.40 0.35 0.002 11.97 0.43 1.91 7.80 0.28 0.882 8.26 0.30 0.054 9.91 0.35
6 26 0.688 8.41 0.40 7.23 104 12.47 0.48 3.10 7.51 0.29 1.12 8.12 0.31 0.018 10.56 0.41
7 26 1.36 8.01 0.37 8.03 104 12.41 0.48 5.39 7.19 0.28 1.52 7.94 0.30 0.012 10.79 0.42
8 26 1.09 8.14 0.38 0.001 12.27 0.47 5.37 7.19 0.28 0.736 8.37 0.32 0.043 10.05 0.39
9 27 1.95 7.79 0.36 0.001 12.13 0.45 5.26 7.20 0.27 0.968 8.20 0.30 0.022 10.46 0.39
10 29 1.86 7.82 0.31 0.006 11.20 0.39 4.44 7.30 0.25 1.17 8.09 0.28 0.058 9.87 0.34
11 27 3.41 7.46 0.35 0.002 11.88 0.44 5.26 7.20 0.27 0.988 8.19 0.30 0.092 9.60 0.36
12 27 0.965 8.21 0.34 0.001 12.09 0.45 4.65 7.28 0.27 0.746 8.36 0.31 0.090 9.61 0.36
13 28 0.562 8.53 0.36 5.69 104 12.61 0.45 2.22 7.71 0.28 0.539 8.55 0.30 0.081 9.67 0.34
14 27 0.523 8.57 0.38 3.39 104 12.92 0.48 1.94 7.79 0.29 1.05 8.15 0.30 0.046 10.01 0.37
15 28 2.30 7.69 0.34 0.002 11.81 0.42 8.77 6.90 0.25 0.937 8.22 0.29 0.132 9.39 0.34
16 28 0.483 8.62 0.38 7.94 104 12.41 0.44 1.66 7.88 0.28 0.634 8.46 0.30 0.024 10.40 0.37
17 28 0.391 8.74 0.38 3.57 104 12.89 0.46 1.33 8.01 0.29 0.482 8.62 0.31 0.016 10.61 0.38
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LE ¼ DGb
HAC
(1)
It should be noticed that cytotoxic effects of selected com-
pounds were previously evaluated in vitro by the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assayagainst A549 (human alveolar basal epithelial adenocarcinoma),
HT29 (human colorectal adenocarcinoma), HT1080 (human ﬁbro-
sarcoma) and MCF-7 (human breast adenocarcinoma) cell lines
[25].
AutoDock driven binding afﬁnities in terms of DGb, ki and LE
were subjected to linear regression analysis vs in vitro cytotoxic
activities [25] to ﬁnd a most satisfying model. On the basis of ac-
quired data, relatively adaptable correlation could just be achieved
Fig. 3. Correlation curve between experimentally determined log(inhibition%) and
estimated binding afﬁnities toward telomerase and EGF for 1,3,4-oxadiazole
derivatives.
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(Fig. 3) within A549 cell line. It is proposed that blocking telome-
rase and EGF might be further exploited as possible mechanism for
cytotoxic activity of 1,3,4-oxadiazoles in adenocarcinoma human
alveolar basal epithelial cancer cells (A549). Subsequent targets
which exhibited intermediate correlations were HDAC and Bcl-2
with regression coefﬁcients of 0.47 and 0.45, respectively.
In the case of Bcl-2, EGF, ENR, FAK, GSK-3 beta, telomerase, and
VEGF, it was found interestingly that docked top-ranked ligand also
exhibited highest LE (independently or along with another mole-
cule). However, in the case of HDAC, MetAP, and TS, compounds
possessing superior LE values (6, 3, and 1, respectively) were not
necessarily the ones with top-ranked binding energies (17, 14, and
17). Such observation emphasized that within Bcl-2, EGF, ENR, FAK,
GSK-3 beta, telomerase, and VEGF, there might be a good correla-
tion between the estimated afﬁnity and corrected afﬁnity of mol-
ecules with regard to their size.
Careful comparison of DGb values among different targets
(Table 3) demonstrated that binding afﬁnity of ligands toward
MetAP was superior to the other targets (11.20 to 12.92 kcal/
mol). However, MetAP could not exert this preferential afﬁnity
when correlated with different cell line IC50 values.3.2. Structure binding relationship (SBR)
Binding characteristics of the top-ranked 1,3.4-oxadiaoles
within each interacted target is summarized in Table 4.
Considering various R1 and R2 substituents within general
structure of oxadiazole compounds (Table 1), binding models
differed among docked ligands and regarding the results, following
SBRs were rationalized:
C It was previously revealed that incorporation of halogen
atoms in 5-substituted phenyl ring and N-benzyl moieties
improved the cytotoxic activity against A549, HT29, HT1080
and MCF-7 cell lines [25]. Interestingly such observation was
in accordance with new ﬁndings in a way that compounds 4
and 17were top-ranked ligands in two and six of the docked
targets, respectively (Table 4).
C Unlike compound 4 that bears 3,4-dichloro substituent,
compound 5 with varied substitution pattern (2,4-dichloro-
5-ﬂouro) was recognized as false negative in modeling sim-
ulations, since it previously exhibited good cytotoxic effects
against A549, HT29, HT1080 and MCF-7 cell lines [25].
C Comparison of DGb for compounds 16 and 17 (Table 3)
pointed that 3,4-dichloro benzyl group provided increased
inhibitory activity against Bcl-2, telomerase and HDAC.
C Interaction models showed that secondary benzyl amine,
pyrrole NH, and N3 of oxadiazole ring participated in H-bond
interactions within various docked targets. It was also found
that oxygen and N4 atoms of oxadiazole ring had a littleparticipation in H-bond interactions with the residues of
desired targets.
C In the case of GSK-3 beta, the key residue participated in H-
bond interaction with all ligands was Val135. Accordingly,
Tyr67 (Bcl-2), Asp855 (EGF), Ser91 (ENR), Glu471 (FAK),
Gly154 (HDAC), His231 (MetAP), Phe494 (telomerase),
His190 and Asn220 (TS, and Glu885) and Asp1046 (VEGF)
were recognized as key residues involved in H-bond
interactions.
C Participation of pyrrole ring in H-bond interactions with Bcl-
2 (Tyr76), telomerase (Phe494), HDAC (His145), GSK-3 beta
(Ile62), MetAP (Asn329), TS (His190) and VEGF (Val899)
demonstrated that it could be chosen as an important
inhibitory moiety against mentioned targets. Results of pre-
vious inhibitory structures [10] and also H-bond interaction
characteristics (Table 4) were in agreement with this
rationalization.
C For comparison purposes, Autodock driven free binding en-
ergies for top-ranked ligands were compared to that of co-
crystallographic ones (Table 5). As can be seen from the
data, top-ranked oxadiazole molecules exhibited superior
binding afﬁnities than co-crystallographic ligands toward
ENR, GSK-3 beta, MetAP and TS.3.3. SAR/SBR refreshment
On the basis of estimated docking results and previously studied
2,5-disubstituted 1,3,4-oxadiazoles with relatively good cytotoxic
activity [10], following schematic SAR/SBR for candidate oxadia-
zoles was offered (Fig. 4).
In general, the cytotoxic activity of 1,3,4-oxadiazole derivatives
seemed to be dependent on the nature of the substituent rather the
core skeleton of the molecule. However, H-bond interaction pat-
terns of targets under study clariﬁed that depending on the anti-
cancer target, 1,3,4-oxadiazole nucleus can blurt cytotoxic activity.
Regarding the structures of best docked ligands and their important
interacting groups, a series of 1,3,4-oxadiazole derivatives were
proposed (Fig. 5) and validated via docking into the mostly
inhibited targets (Bcl-2, EGF, HDAC, MetAP and telomerase). Ra-
tionales behind designation of the proposed compounds were as
follows:
C According to the importance of substituents adjacent to
1,3,4-oxadiazole nucleus and re-checking the best docked
structures (4 and 17), 3,4-dichloro substituted phenyl rings
(R1 and R2) were incorporated into the proposed structures
(Fig. 6: a-d). This incorporation is schematically depicted in
Fig. 5 (see Figs. 7 and 9).
C Inclusion of sulﬁde linkage is due to its recognition in the
structure of the majority of the previously EGF and telome-
rase inhibitors [10]. Moreover; it has also been reported that
sulfur is an important atom for TS inhibition (Fig. 6: a-c) [10].
C Due to the previous studies on HDAC inhibitors, Zn2þ binding
group along with linker and surface recognition moiety were
required for efﬁcient inhibition of HDAC [10]. For this pur-
pose, Zn2þ binding hydroxamate group was added to the
proposed structures (Fig. 6: a and b).
C To mimic the amino oxadiazole moiety in previously re-
ported derivatives [77], carbon atom between amine group
and 1,3,4-oxadiazole heterocycle was moved to the prox-
imity of pyrrole ring to propose a new HDAC inhibitor with
aminopyrrole moiety as a new linker to both surface recog-
nition cap and zinc binding group (Fig. 6: b, c and d).
Table 4
Hydrophobic and H-bond interaction characteristics for docked oxadiazole derivatives into the active site of chemotherapeutic targets.
Target PDB
code
Best docked
ligand code
Estimated
Ki (mM)
Residues involved in
hydrophobic contacts
Residues involved
in H-bonds
H-bond
distances (Å)a
Atoms of ligand involved
in H-bonds
Atoms of residue
involved in H-bonds
Bcl-2 4AQ3 17 1.520 Phe63, Tyr67
Asp70, Phe71
Met74, Glu95
Leu96, Arg98
Asp99, Arg105
Phe112
Tyr67 2.84 NH (pyrrole) OH (side chain hydroxyl)
EGF 3W33 17 0.008 Leu718, Val726
Ala743, Lys745
Met766, Cys775
Arg776, Leu777
Leu788, Thr790
Thr854, Asp855
Phe856
Asp855
Asp855
Thr854
2.92
2.98
3.01
NH (amine)
N3 (oxadiazole)
NH (amine)
O (side chain carboxylate)
O (side chain carboxylate)
C¼O (backbone)
ENR 1QSG 4 0.115 Gly13, Ala15
Ser19, Ile20
Ser91, Ile92
Gly93, Leu144
Tyr146, Lys163
Ala189, Gly190
Pro191, Ile192
Thr194, Leu195
Ala196, Ala197
Phe203
Ser91
Ser91
Ser91
2.78
2.97
3.05
NH (amine)
NH (amine)
NH (amine)
C¼O (backbone)
C¼O (backbone)
C¼O (backbone)
FAK 4KAO 12 0.047 Val436, Ala452
Lys454, Glu471
Thr474, Met475
Phe478, Val484
Met499, Gly563
Asp564, Phe565
Asp564
Glu471
2.75
3.24
NH (amine)
NH (amine)
C¼O (backbone)
O (side chain carboxylate)
GSK-3 beta 1Q41 17 0.153 Ile62, Ala83
Val110, Leu132
Asp133, Tyr134
Val135, Pro136
Thr138, Arg141
Leu188, Cys199
Val135
Val135
Ile62
2.64
2.78
2.98
NH (amine)
N3 (oxadiazole)
NH (pyrrole)
C¼O (backbone)
C¼O (backbone)
C¼O (backbone)
HDAC 5IX0 17 0.391 Met35, Asp104,
Leu144,His146 Gly154,
Phe155 Cys156, Asp181
His183, Asp186,
Tyr209, Phe210 Asp269,
Leu276 Gly305,
Gly306 Tyr308
His146 2.68 N2 (oxadiazole) NH (side chain imidazole)
MetAP 1YW7 14 0.003 Phe219, Pro220
His231, Asp251
Asp262, Leu328
Asn329, His331
Ile338, Glu364
His382, Tyr383
Met384, Ala414
Tyr444, Glu459
Asn329
Glu364
His231
2.75
2.77
3.14
NH (pyrrole)
NH (amine)
O (oxadiazole)
C¼O (backbone)
O (side chain carboxylate)
NH (side chain imidazole)
Telomerase 5CQG 17 1.330 Met482, Met483
Arg486, Asp493
Phe494, Gly495
Ile497, Trp498
Ile550, Tyr551
Leu554, Arg557
Phe494 2.69 NH (pyrrole) C¼O(backbone)
TS 4E5O 17 0.482 Glu81, Ile102
Trp103, Tyr129
Cys189, His190
Gln208, Ser210, Gly211,
Asp212
Gly216, Phe219
Asn220, His250
Glu81
His190
Asn220
2.68
3.03
3.27
NH (amine)
NH (pyrrole)
O (oxadiazole)
O (side chain carboxylate)
NH (side chain imidazole)
NH (side chain amine)
VEGF 3VO3 4 0.004 Leu840, Val848
Val867, Lys868
Ala866, Glu885
Leu889, Val898
Val899, Val914
Val916, Glu917
Phe918, Leu1035
Ile1044, Cys1045
Asp1046, Phe1047
Glu885
Asp1046
Val899
2.59
2.88
2.96
NH (amine)
N3 (oxadiazole)
NH (pyrrole)
O (side chain carboxylate)
C¼O (backbone)
C¼O (backbone)
a H-bond distances are reported as (H… acceptor) lengths.
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Table 5
Simulation results for superior docked ligands into the active site of chemotherapeutic targets.
Target PDB code Best docked ligand code DGb (kcal/mol) docked ligand DGb (kcal/mol) cognate ligand
Bcl-2 4AQ3 17 7.92 12.43
EGF 3W33 17 11.06 12.89
ENR 1QSG 4 9.46 8.81
FAK 4KAO 12 10.30 12.88
GSK-3 beta 1Q41 17 10.30 9.65
HDAC 5IX0 17 8.74 11.04
MetAP 1YW7 14 12.92 6.57
Telomerase 5CQG 17 8.01 10.69
TS 4E5O 17 8.62 7.35
VEGF 3VO3 4 11.39 13.10
Fig. 4. Schematic representation of SAR/SBR for 1-(5-aryl-1,3,4-oxadiazol-2-yl)-1-(1H-pyrrol-2-yl) methanamines toward chemotherapeutic targets.
R. Alikhani et al. / Journal of Molecular Structure 1164 (2018) 9e2216C Previous studies revealed that 1,4-benzodioxane containing
oxadiazoles were efﬁcient telomerase, GSK-3 beta and
MetAP inhibitors [10]. Accordingly, a dioxane ring was fused
to the benzyl group and two Cl atoms were moved to the
dioxane ring. This possible solution led to the designation of
compound e (Fig. 6: e).Fig. 5. Incorporating different aryl scaffolds of 1,3,4-oxadiazoles into a hybrid
structure.
Fig. 6. Chemical structures of the proposed 1,3,4-oxadiazole derivatives with potential
multi-chemotherapeutic target inhibitory activities.
Fig. 7. 2D scheme of binding interactions between proposed compound b (left)/best docked ligand (right) and telomerase (PDB ID: 5CQG) generated by LIGPLOT.
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Compounds a-e were docked into the active sites of desired
macromolecules (Bcl-2, EGF, HDAC and telomerase). Comparing
DGb values of proposed and best docked ligands for each target
demonstrated that compounds a and b exhibited better binding
ability within all quadruple targets (Table 6). Since MetAP exhibited
a noticeable superiority in terms of DGb values among all targets
(refer to Table 3), we supposed to dock these ligands into the MetAP
as well. Results showed that except compounds a and e, three other
molecules exhibited weaker binding afﬁnities toward MetAP when
compared to top-ranked docked ligand (Table 6). Moreover;
modeling study might not support the important role of Zn2þ
binding hydroxamate since binding afﬁnity of compound c
(9.61 kcal/mol) was not so different with that of a and b (9.65
& 9.53 kcal/mol).
Compounds a, b and e exhibited superior docking results within
intended targets. However, we can signify the spectacular role of a
regarding its enhanced inhibitory activity against all quintet tar-
gets. Beside compound a, interestingly, compounds b and e were
the forefront molecules in afﬁnity ranking due to their relatively
lower DGb values within targets (except b toward MetAP and e
toward HDAC). Due to the superiority of b in binding to telomerase,
2D schematic representation of binding interactions are depicted in
Fig. 8.Table 6
Binding afﬁnity of proposed oxadiazole structures and best docked oxadiazoles vs select
Comp.
code
Bcl-2 EGF HDAC
DGba best
docked ligand
(kcal/mol)
DGb proposed
ligand (kcal/
mol)
DGb best
docked ligand
(kcal/mol)
DGb proposed
ligand (kcal/
mol)
DGb best
docked ligand
(kcal/mol)
a 7.92 8.30 11.06 11.30 8.74
b 7.92 8.24 11.06 12.27 8.74
c 7.92 7.49 11.06 10.78 8.74
d 7.92 7.84 11.06 10.74 8.74
e 7.92 8.48 11.06 12.25 8.74
a DGb values were introduced form Table 5.Results of docking compound e into the active site of Bcl-2, EGF,
HDAC, MetAP and telomerase conﬁrmed our assumption since
better DGb values were achieved in all targets except HDAC
(Table 6). Due to the inhibition of GSK-3 beta by 1,4-benzodioxane
substituted oxadiazoles [10], compound e was docked into the
active site of GSK-3 beta as well and superior DGb values afﬁrmed
our designation (DGb for best docked ligand and proposed ligand
were 10.30 and 11.01 kcal/mol, respectively). Designation of a
1,4-benzodioxan containing oxadiazole (e) resulted in considerable
increase in binding afﬁnities toward assessed targets, except HDAC
(Table 6). Moreover, oxygen atoms of dioxane ring and its 2,3-
dichloro substituent participated in H-bond and electrostatic in-
teractions, respectively (Fig. 8)
3.4.1. Effect of sulfur linkage
It was primarily supposed that incorporation of sulﬁde linkage
might enhance the binding ability of oxadiazoles via possible hy-
drophobic interactions. Since the mere structural difference of
compounds c and dwas attributed to the presence of sulfur moiety
in c (Fig. 6), comparative evaluation of intermolecular binding in-
teractions might be informative. At ﬁrst glance, results of Table 6
showed that within Bcl-2 and HDAC, sulfur containing molecule
(c) was identiﬁed as weaker binder while in the case of MetAP and
telomerase, it seemed that sulfur linkage enhanced the binding
capability. Moreover; compounds c and d did not show anyed chemotherapeutic targets.
MetAP Telomerase
DGb proposed
ligand (kcal/
mol)
DGb best
docked ligand
(kcal/mol)
DGb proposed
ligand (kcal/
mol)
DGb best
docked ligand
(kcal/mol)
DGb proposed
ligand (kcal/
mol)
9.65 12.92 13.40 8.01 9.35
9.53 12.92 10.91 8.01 11.47
9.61 12.92 9.99 8.01 10.05
10.09 12.92 9.56 8.01 9.68
8.11 12.92 14.35 8.01 10.41
Fig. 8. 2D scheme of binding interactions between proposed compound e (left)/best docked ligand (right) and MetAP (PDB ID: 1YW7) generated by LIGPLOT.
Fig. 9. 2D scheme of binding interactions between proposed compound c, Bcl-2 (PDB
ID: 4AQ3) and EGF (PDB ID: 3W33) generated by LIGPLOT.
Fig. 10. 2D scheme of binding interactions between proposed compound c and MetAP
(PDB ID: 1YW7) generated by LIGPLOT.
Fig. 11. 2D scheme of binding interactions between proposed compound c and telo-
merase (PDB ID: 5CQG) generated by LIGPLOT.
R. Alikhani et al. / Journal of Molecular Structure 1164 (2018) 9e2218meaningful difference in binding toward EGF.
To further elucidate the above observations, 2D schematic
binding models of designated ligands were depicted in Figs. 10e12.
Within Bcl-2 and EGF active sites, sulfur atom participated in just
one hydrophobic contact with Val92 (Bcl-2) and Arg841 (EGF) but
careful inspection of Figs. 10 and 11 revealed more hydrophobic
contacts for sulfur atom. This was possibly in accordance with ob-
tained binding energy values (refer to Table 6) and emphasized on
important role of sulfur linkage in making efﬁcient lipophilic
interactions.
3.4.2. Zn2þ binding moiety
According to the importance of Zn2þ cofactor in ligand/receptor
interactions within HDAC active site, binding interactions between
Fig. 12. Binding interaction comparison of docked oxadiazole compounds (aee) into HDAC active site (PDB ID: 5IX0).
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study. Moreover, oxadiazole nucleus was previously introduced as a
surface recognition group for HDAC inhibition [10,15] (Fig. 4). In this
regard, schematic binding patterns of 17 within HDAC active site
represented that oxadiazole N2 atom participated in pseudo cation-
p interaction with Zn2þ cofactor (bond distance 3.02 Å) (Fig. 12).
Binding interaction analysis of proposed compounds within HDAC
active site demonstrated that Zn2þ interactedwith oxadiazole N2 (a
and d), oxadiazole N3 and pyrrole NH (c). Unexpectedly, although
hydroxamate group was previously considered as a Zn2þ binding
group, but it did not participate in any binding interactions with
Zn2þ (relatively high distance, 7.02 Å in a and 6.41 Å in b).
Another interesting point to mention is the lack of ligand-Zn2þ
interactions in b and e regarding their similar structural fragments
to a (Fig. 12). A closer look at intermolecular binding models
(Fig. 12) notiﬁed that such observation might be attributed to the
shortened linker between oxadiazole and pyrrole and also
replacement of chiral carbon (a) with nitrogen in b which induced
different inversion pattern. In other words, relatively similar DGb
values of a and b (9.65 & 9.53 kcal/mol, respectively) might be
explained by multiple hydrophobic interactions of b via its
hydroxamate substituent that could signiﬁcantly compensate the
absence of ligand-Zn2þ interactions.
Lack of ligand-Zn2þ interactions for emay be rationalized by the
presence of dichloro dioxane ring despite the presence of identical
linker when compared to a. Careful inspection of Fig. 12 showed
that despite the pyrrole nitrogen, dichloro dioxane of e participated
in multiple hydrophobic contacts with Leu276 while similar inter-
action was recorded with just pyrrole ring in a. Besides the lack of
ligand-Zn2þ interactions, lower binding ability of e (8.11 kcal/mol)
with regard to a and b, might be related to fewer H-bond in-
teractions as another important binding feature (Fig. 12e).Fig. 13. Ligand-residue binding energies of cancer relevant targets and docked N-(3,4-
Dichlorobenzyl)-1-[5-(4-bromophenyl)-1,3,4-oxadiazol-2-yl]-1-(1H-pyrrol-2-yl)meth-
anamines (17).3.5. QM studies
N-(3,4-Dichlorobenzyl)-1-[5-(4-bromophenyl)-1,3,4-oxadiazol-
2-yl]-1-(1H-pyrrol-2-yl)methanamines (17) was previously ranked
as one of the most cytotoxic agents in A549 (IC50 17.3 mM) and HT29
(IC50 20 mM) cell lines [25]. In addition; molecular docking simu-
lations recognized 17 as the top-ranked ligand within Bcl-2, EGF,
GSK-3 beta, HDAC, telomerase and TS active sites and relativelysatisﬁed in silico in vitro correlation model could be established for
17 in the case of telomerase (R2¼ 0.52).
In the light of above explanations, 17 might be an appropriate
candidate for intermolecular binding energy analysis in terms of
individual interacted residues. For this purpose, telomerase com-
plex was introduced into the QM job. Ligand-residue binding en-
ergies (DEb) were estimated by Eq. (2):
DEb ¼ ELR  ER  EL (2)
ELR stands for ligand-residue interaction energy, while ER and EL
indicate the electronic energies of unbound residues and ligand,
respectively. Binding energies of inhibitor (17) with individual
amino acid residues surrounding the target binding sites at the
B3LYP/Def2-SVP level of calculation are summarized in Fig. 13.
Fig. 14. Possible electrostatic interactions between telomerase active site and com-
pound 17 (PDB ID: 5CQG), electrostatic surfaces were considered for just phenyl rings
of ligand and residue.
R. Alikhani et al. / Journal of Molecular Structure 1164 (2018) 9e2220As can be understood from the data, lowest binding energy in
the B3LYP/Def2-SVP level of calculation was dedicated to Arg486
(6.05 kcal/mol). 2D schematic representation of interactions
indicated that Arg486 might be involved in hydrophobic contact
and electrostatic Van der waals interactions with bromophenyl
moiety directly attached to the oxadiazole ring. Careful inspection
of the 3D interaction diagrams revealed that phenyl ring of Phe494
side chain might be located in an appropriate spatial orientation
with regard to both phenyl rings of 17 (Fig. 14). Such stereo orien-
tation might provide a possible p-p stacking contacts within aro-
matic rings. Moreover it was found that carbonyl oxygen of
backbone made H-bond with pyrrole NH (2.69 Å). Ligand-Phe494
interactions were associated with about 2.23 kcal/mol binding
energy in our level of study.
Weak binding interactions (binding energy 0.24 kcal/mol)
were recorded in the case of Gly495 which participated in hydro-
phobic contacts within carbon atoms of pyrrole adjacent to NH.4. Conclusion
Various studies have demonstrated 1,3,4-oxadiazole heterocy-
clic nucleus as a privileged medicinal scaffold. A series of novel
synthesized 2,5-disubstituted 1,3,4-oxadiazole derivatives were
subjected to in silico analysis of intermolecular binding interactions
with some of the cancer relevant oxadiazole-inhibited targets.
Structure based computational modeling of novel synthesized
cytotoxic (3,4-Dichlorobenzyl)-1-[5-(4-bromophenyl)-1,3,4-
oxadiazol-2-yl]-1-(1H-pyrrol-2-yl)methanamines (1e17) exhibi-
ted the contribution of H-bonds, p-p stacking and Van der Waals
interactions in potential binding to validated chemotherapeutic
targets (DGbs of 5.50 to 12.89 kcal/mol). Molecular docking
simulation proposed that candidate oxadiazoles interactedwith the
active site of MetAP with estimated DGb of 11.20 to 12.92 kcal/
mol. In silico structure binding relationship (SBR) studies
conﬁrmed that chemical structures possessing chlorine and
bromine atoms on 5-substituted phenyl and N-benzyl rings (4 and17) exhibited superior binding modes/energies with regard to the
majority of studied targets. Binding efﬁciency as a modern concept
for consideration of binding afﬁnity with regard to heavy atom
number (efﬁcient binding) was incorporated in our study and it was
found that in the case of Bcl-2, EGF, ENR, FAK, GSK-3 beta, telo-
merase, and VEGF, docked top-ranked ligand also exhibited highest
LE values. On the basis of obtained results, a general SAR/SBR
pattern for candidate 1,3,4-oxadiazoles were offered and a few
hybrid oxadiazole structures were proposed as potential anticancer
agents. Intermolecular binding energy analysis was performed on
17 within telomerase as the representative of the best in silico
in vitro correlated system. On the basis of QM analysis, Arg486,
Phe494, Gly495, Ile550, Tyr551 and Arg557 were found to be the
dominant attractive residues participating in H-bond and Van der
waals interactions within telomerase active site. Since the assessed
macromolecular targets were previously proved to be blocked by
1,3,4-oxadiazoles, results of this study might be useful in further
design of more potent cytotoxic 1,3,4-oxadiazole derivatives.
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